Back to Search Start Over

Supplementary Table 2 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORĪ³ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Authors :
H. Jeffrey Wilkins
Marshall Schreeder
Xiao Hu
Laura Carter
Garry Weems
John Nemunaitis
John Sarantopoulos
Erika P. Hamilton
Judy S. Wang
Devalingam Mahalingam
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Fold induction over Day 1 pre-dose.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....018d87e7dfac7d80c8c4c814cce840ab

Tools

Authors Abstract Subjects Details